Johnson & Johnson 340B Rebate Model Threat Halted Due to Advocates Like the North Carolina Community Health Center Association.
On September 30, 2024 Johnson & Johnson (J&J) announced it was ending its plans to implement a 340B rebate model for two of its drugs, Stelara and Xarelto. The immediate halt to the rebate model was prompted by the Health Resources and Services Administration’s (HRSA) September 27 letter threatening to terminate J&J’s participation in the…